LY2605541
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Neutral Protamine Hagedorn insulin with an intermediate action profile has been in use for many years for the treatment of Type 1…
The impact of the novel basal insulin LY2605541 (LY) on hepatic and nonhepatic glucose uptake (non-HGU) was evaluated. Conscious…
To assess the pharmacokinetics (PK) and glucodynamics (GD) of LY2605541 in patients with type 2 diabetes mellitus.
There is a clinical rationale for a basal insulin with a predictable action and low inter‐ and intra‐individual variability…
OBJECTIVE To use continuous glucose monitoring (CGM) to evaluate the impact of the novel, long-acting basal insulin analog…
The first generation of basal insulin analogs, insulin glargine and detemir, are characterized by a more predictable day-to-day…
The basal insulin analogue LY2605541, a PEGylated insulin lispro with prolonged duration of action, was previously shown to be…
Abstract Background: Because insulin dosing requires optimization of glycemic control, it is important to use a single metric of…